作者用炔羟雄烯唑(danazol)治疗21例来作选择的难治性慢性贫血。全部病人先前均曾用补血剂、雄激素、皮质类固醇、大剂量静脉注射免疫球蛋白、抗胸腺球蛋白,细胞毒性免疫抑制剂和/或血浆交换治疗,结果无效或不能耐受治疗。21例中3例为纯红细胞再生障碍、3例再生障碍性贫血、2例阵发性睡眠性血红蛋白尿、2例骨髓纤维化,11例骨髓异常增生综合征。全部患者治疗开始时均需依靠输血(血红蛋白≤7g％)。炔羟雄烯唑开始剂量为800mg/d,分4次口服,至少6周。完全有效为血红蛋白完全正常 The authors treated 21 patients with alkyne and danazol to treat refractory chronic anemia. All patients have previously been treated with hematologic agents, androgens, corticosteroids, high-dose intravenous immunoglobulin, anti-thymosin, cytotoxic immunosuppressive agents, and / or plasma exchange, resulting in ineffective or intolerable treatment. Three of the 21 patients had pure red cell aplasia, 3 had aplastic anemia, 2 had paroxysmal nocturnal hemoglobinuria, 2 had myelofibrosis, and 11 had myelodysplastic syndrome. All patients need to rely on blood transfusion (hemoglobin ≤ 7g%) at the beginning of treatment. The initial dose of alkyne androstenediazole was 800 mg / d orally in 4 doses for at least 6 weeks. Completely effective for hemoglobin completely normal